You are here: Industry Insights > Shire

News List

Shire submits marketing application for lifitegrast to treat dry eye disease in Europe pharmaceutical-technology
August 18, 2017
Shire has filed marketing authorisation application (MAA) for lifitegrast as a treatment for patients with dry eye disease in Europe.
Shire submits dry eye drug in Europe pharmatimes
August 16, 2017
Shire has filed for approval of lifitegrast in Europe for dry eye disease in the hope of securing approval for the first treatment in a new class of drugs to address signs and symptoms of the condition.
Shire files dry-eye drug lifitegrast for marketing approval pharmafile
August 16, 2017
Shire has announced that it has submitted its dry-eye drug for European marketing approval, a year after it had gained approval in the US for the treatment of dry eye disease.
Shire Reports Q2 2017 Operating Results americanpharmaceuticalreview
August 08, 2017
Shire announced unaudited results for the three months ended June 30, 2017.
Shire mulls over separation of neuroscience unit pharmatimes
August 07, 2017
Shire is considering cleaving its neuroscience division into a separate, publicly-listed entity in a move that would afford the firm a sharper focus on rare diseases
Shire targeted by potential buyers in EU, US: report firstwordpharma
July 27, 2017
Some of the largest drugmakers in the EU and US have hired advisers regarding a potential Shire acquisition.
CSL launches Cinryze rival Haegarda despite Shire's best efforts—at a big discount, too fiercepharma
July 21, 2017
Shire fought hard to stop it, but no dice: CSL has now launched its hereditary angioedema med Haegarda, and it’s done so with its eye on Shire’s market share.
Shire expands broad monoclonal antibody research platform cphi-online
July 20, 2017
Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.
Shire submits IND application to FDA for gene therapy candidate SHP654 for treatment of hemophilia A cphi-online
July 13, 2017
SHP654 aims to deliver sustained protection against bleeds for patients with hemophilia A.
Shire injunction blocks Roche’s ‘misleading’ statements on haemophilia drugs pharmaphorum
July 11, 2017
Shire has taken out an injunction limiting how Roche can talk about its haemophilia drug, as the two companies fight for a share of this $11 billion market.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page